157 related articles for article (PubMed ID: 25170013)
1. A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer.
Gold KA; Lee JJ; Harun N; Tang X; Price J; Kawedia JD; Tran HT; Erasmus JJ; Blumenschein GR; William WN; Wistuba II; Johnson FM
Oncologist; 2014 Oct; 19(10):1040-1. PubMed ID: 25170013
[TBL] [Abstract][Full Text] [Related]
2. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
Sequist LV; Gray JE; Harb WA; Lopez-Chavez A; Doebele RC; Modiano MR; Jackman DM; Baggstrom MQ; Atmaca A; Felip E; Provencio M; Cobo M; Adiwijaya B; Kuesters G; Kamoun WS; Andreas K; Pipas JM; Santillana S; Cho BC; Park K; Shepherd FA
Oncologist; 2019 Aug; 24(8):1095-1102. PubMed ID: 30975923
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
Haura EB; Tanvetyanon T; Chiappori A; Williams C; Simon G; Antonia S; Gray J; Litschauer S; Tetteh L; Neuger A; Song L; Rawal B; Schell MJ; Bepler G
J Clin Oncol; 2010 Mar; 28(8):1387-94. PubMed ID: 20142592
[TBL] [Abstract][Full Text] [Related]
4. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Wheler J; Falchook G; Tsimberidou AM; Hong D; Naing A; Piha-Paul S; Chen SS; Heymach J; Fu S; Stephen B; Fok JY; Janku F; Kurzrock R
Oncotarget; 2013 May; 4(5):772-84. PubMed ID: 23800712
[TBL] [Abstract][Full Text] [Related]
5. Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
Macaulay VM; Middleton MR; Eckhardt SG; Rudin CM; Juergens RA; Gedrich R; Gogov S; McCarthy S; Poondru S; Stephens AW; Gadgeel SM
Clin Cancer Res; 2016 Jun; 22(12):2897-907. PubMed ID: 26831715
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
Johnson ML; Riely GJ; Rizvi NA; Azzoli CG; Kris MG; Sima CS; Ginsberg MS; Pao W; Miller VA
J Thorac Oncol; 2011 Jun; 6(6):1128-31. PubMed ID: 21623279
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L).
Kimura T; Kawaguchi T; Chiba Y; Yoshioka H; Watanabe K; Kijima T; Kogure Y; Oguri T; Yoshimura N; Niwa T; Kasai T; Hayashi H; Ono A; Asai K; Tanaka H; Yano S; Yamamoto N; Nakanishi Y; Nakagawa K
Jpn J Clin Oncol; 2019 Oct; 49(10):947-955. PubMed ID: 31242302
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913.
Nakahara Y; Shimokawa T; Misumi Y; Nogami N; Shinkai T; Seki N; Hosomi Y; Hida N; Okamoto H
Invest New Drugs; 2021 Feb; 39(1):202-209. PubMed ID: 32803700
[TBL] [Abstract][Full Text] [Related]
9. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320).
Otani S; Sasaki J; Nakahara Y; Fukui T; Igawa S; Naoki K; Bessho A; Hosokawa S; Fukamatsu N; Nakamura Y; Kasai T; Sugiyama T; Tokito T; Seki N; Hamada A; Okamoto H; Masuda N
Invest New Drugs; 2021 Apr; 39(2):530-536. PubMed ID: 33159674
[TBL] [Abstract][Full Text] [Related]
11. Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
Tarhini AA; Rafique I; Floros T; Tran P; Gooding WE; Villaruz LC; Burns TF; Friedland DM; Petro DP; Farooqui M; Gomez-Garcia J; Gaither-Davis A; Dacic S; Argiris A; Socinski MA; Stabile LP; Siegfried JM
Cancer; 2017 Aug; 123(15):2936-2944. PubMed ID: 28472537
[TBL] [Abstract][Full Text] [Related]
12. A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.
Gray JE; Haura E; Chiappori A; Tanvetyanon T; Williams CC; Pinder-Schenck M; Kish JA; Kreahling J; Lush R; Neuger A; Tetteh L; Akar A; Zhao X; Schell MJ; Bepler G; Altiok S
Clin Cancer Res; 2014 Mar; 20(6):1644-55. PubMed ID: 24429877
[TBL] [Abstract][Full Text] [Related]
13. Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.
Ou SI; Govindan R; Eaton KD; Otterson GA; Gutierrez ME; Mita AC; Argiris A; Brega NM; Usari T; Tan W; Ho SN; Robert F
J Thorac Oncol; 2017 Jan; 12(1):145-151. PubMed ID: 27697581
[TBL] [Abstract][Full Text] [Related]
14. Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
Miyamoto S; Azuma K; Ishii H; Bessho A; Hosokawa S; Fukamatsu N; Kunitoh H; Ishii M; Tanaka H; Aono H; Nakahara Y; Kusaka K; Hosomi Y; Kikuchi N; Mori Y; Itani H; Hamada A; Yamada K; Okamoto H
JAMA Oncol; 2020 Jul; 6(7):e201250. PubMed ID: 32407455
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis.
Wu FZ; Song JJ; Zhao ZW; Huang XF; Mao JT; Tu JF; Chen MJ; Chen WQ; Fang SJ; Zheng LY; Fan XX
Math Biosci Eng; 2019 Aug; 16(6):7921-7933. PubMed ID: 31698647
[No Abstract] [Full Text] [Related]
16. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
Rosell R; Dafni U; Felip E; Curioni-Fontecedro A; Gautschi O; Peters S; Massutí B; Palmero R; Aix SP; Carcereny E; Früh M; Pless M; Popat S; Kotsakis A; Cuffe S; Bidoli P; Favaretto A; Froesch P; Reguart N; Puente J; Coate L; Barlesi F; Rauch D; Thomas M; Camps C; Gómez-Codina J; Majem M; Porta R; Shah R; Hanrahan E; Kammler R; Ruepp B; Rabaglio M; Kassapian M; Karachaliou N; Tam R; Shames DS; Molina-Vila MA; Stahel RA;
Lancet Respir Med; 2017 May; 5(5):435-444. PubMed ID: 28408243
[TBL] [Abstract][Full Text] [Related]
17. Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Kelley MJ; Jha G; Shoemaker D; Herndon JE; Gu L; Barry WT; Crawford J; Ready N
Cancer Invest; 2017 Jan; 35(1):32-35. PubMed ID: 27911119
[TBL] [Abstract][Full Text] [Related]
18. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
Yoshioka H; Azuma K; Yamamoto N; Takahashi T; Nishio M; Katakami N; Ahn MJ; Hirashima T; Maemondo M; Kim SW; Kurosaki M; Akinaga S; Park K; Tsai CM; Tamura T; Mitsudomi T; Nakagawa K
Ann Oncol; 2015 Oct; 26(10):2066-72. PubMed ID: 26153496
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer.
Lara MS; Holland WS; Chinn D; Burich RA; Lara PN; Gandara DR; Kelly K; Mack PC
Clin Lung Cancer; 2017 May; 18(3):281-285. PubMed ID: 28038979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
